Table 1.
Demographics and biochemical characteristics (Mean±SE) of the study groups
| Parameter | CKD Patients (n=337) | Healthy Controls (N=36) | ||
|---|---|---|---|---|
| HDCKD (N-290) Stage: v | HDCKD- suspected EPO hypo response (N=9); Stage: v | NDCKD (N=38) Stage: iv & v | ||
| Age | 51±15 | 50±17 | 52±12 | 48±14 |
| Male | 164 | 5 | 22 | 19 |
| Female | 124 | 4 | 16 | 17 |
| Anemia (%) | 95 | 93 | 94 | 4 |
| Diabetes (%) | 47 | 51 | 56 | NA |
| Hypertension (%) | 61 | 58 | 58 | NA |
| No of subjects with rHuEPO supplementation | 276 | 9 | Nil | Nil |
| Weekly dose (mean IU) of rHuEPO | 8000 U | 8000 U | NA | NA |
| *Weekly dose (mean mg) of iron | 250 mg | 250 mg | 50-100 mg | NA |
| Time of HD (months) | 25±9 | 23±4 | NA | NA |
| Iron(µg/dL) | 84±5.7 | 139±70 | 66±7 | 68±6 |
| TIBC(µg/dL) | 221±7 | 220±55 | 234±12 | 240±10 |
| % TSAT | 39±2 | 50±9 | 30±3 | 35±3 |
| Ferritin(ng/mL) | 684±37 | 669±126 | 207±28 | 130±14 |
| Tissue iron(mg) | 250±11 | 301±37 | 60±27 | 4±22 |
| Transferrin(mg/dL) | 184±5 | 31±5 | 220±8 | 255±6 |
| Hemoglobin(g/dL) | 8.65±0.2 | 7.63± 0.4 | 8.75±.02 | 14.8±0.2 |
| Urea(mg/dL) | 117±3 | 44±17 | 114±9 | 30±4 |
| Creatinine (mg/dL) | 8.4±2.7 | 9.1±3.1 | 5.3±1.6 | 0.9±0.2 |